BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

765 related articles for article (PubMed ID: 11747915)

  • 1. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial.
    Bojang KA; Milligan PJ; Pinder M; Vigneron L; Alloueche A; Kester KE; Ballou WR; Conway DJ; Reece WH; Gothard P; Yamuah L; Delchambre M; Voss G; Greenwood BM; Hill A; McAdam KP; Tornieporth N; Cohen JD; Doherty T;
    Lancet; 2001 Dec; 358(9297):1927-34. PubMed ID: 11747915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Five-year safety and immunogenicity of GlaxoSmithKline's candidate malaria vaccine RTS,S/AS02 following administration to semi-immune adult men living in a malaria-endemic region of The Gambia.
    Bojang K; Milligan P; Pinder M; Doherty T; Leach A; Ofori-Anyinam O; Lievens M; Kester K; Schaecher K; Ballou WR; Cohen J
    Hum Vaccin; 2009 Apr; 5(4):242-7. PubMed ID: 19276646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequential Phase 1 and Phase 2 randomized, controlled trials of the safety, immunogenicity and efficacy of combined pre-erythrocytic vaccine antigens RTS,S and TRAP formulated with AS02 Adjuvant System in healthy, malaria naïve adults.
    Kester KE; Gray Heppner D; Moris P; Ofori-Anyinam O; Krzych U; Tornieporth N; McKinney D; Delchambre M; Ockenhouse CF; Voss G; Holland C; Beckey JP; Ballou WR; Cohen J;
    Vaccine; 2014 Nov; 32(49):6683-91. PubMed ID: 24950358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy trial of malaria vaccine SPf66 in Gambian infants.
    D'Alessandro U; Leach A; Drakeley CJ; Bennett S; Olaleye BO; Fegan GW; Jawara M; Langerock P; George MO; Targett GA
    Lancet; 1995 Aug; 346(8973):462-7. PubMed ID: 7637479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Four year immunogenicity of the RTS,S/AS02(A) malaria vaccine in Mozambican children during a phase IIb trial.
    Aide P; Dobaño C; Sacarlal J; Aponte JJ; Mandomando I; Guinovart C; Bassat Q; Renom M; Puyol L; Macete E; Herreros E; Leach A; Dubois MC; Demoitie MA; Lievens M; Vekemans J; Loucq C; Ballou WR; Cohen J; Alonso PL
    Vaccine; 2011 Aug; 29(35):6059-67. PubMed ID: 21443960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial.
    Alonso PL; Sacarlal J; Aponte JJ; Leach A; Macete E; Milman J; Mandomando I; Spiessens B; Guinovart C; Espasa M; Bassat Q; Aide P; Ofori-Anyinam O; Navia MM; Corachan S; Ceuppens M; Dubois MC; Demoitié MA; Dubovsky F; Menéndez C; Tornieporth N; Ballou WR; Thompson R; Cohen J
    Lancet; 2004 Oct 16-22; 364(9443):1411-20. PubMed ID: 15488216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial.
    Asante KP; Abdulla S; Agnandji S; Lyimo J; Vekemans J; Soulanoudjingar S; Owusu R; Shomari M; Leach A; Jongert E; Salim N; Fernandes JF; Dosoo D; Chikawe M; Issifou S; Osei-Kwakye K; Lievens M; Paricek M; Möller T; Apanga S; Mwangoka G; Dubois MC; Madi T; Kwara E; Minja R; Hounkpatin AB; Boahen O; Kayan K; Adjei G; Chandramohan D; Carter T; Vansadia P; Sillman M; Savarese B; Loucq C; Lapierre D; Greenwood B; Cohen J; Kremsner P; Owusu-Agyei S; Tanner M; Lell B
    Lancet Infect Dis; 2011 Oct; 11(10):741-9. PubMed ID: 21782519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Duration of vaccine efficacy against malaria: 5th year of follow-up in children vaccinated with RTS,S/AS02 in Mozambique.
    Campo JJ; Sacarlal J; Aponte JJ; Aide P; Nhabomba AJ; Dobaño C; Alonso PL
    Vaccine; 2014 Apr; 32(19):2209-16. PubMed ID: 24631081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protective efficacy of the RTS,S/AS02 Plasmodium falciparum malaria vaccine is not strain specific.
    Alloueche A; Milligan P; Conway DJ; Pinder M; Bojang K; Doherty T; Tornieporth N; Cohen J; Greenwood BM
    Am J Trop Med Hyg; 2003 Jan; 68(1):97-101. PubMed ID: 12556156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, immunogenicity and duration of protection of the RTS,S/AS02(D) malaria vaccine: one year follow-up of a randomized controlled phase I/IIb trial.
    Aide P; Aponte JJ; Renom M; Nhampossa T; Sacarlal J; Mandomando I; Bassat Q; Manaca MN; Leach A; Lievens M; Vekemans J; Dubois MC; Loucq C; Ballou WR; Cohen J; Alonso PL
    PLoS One; 2010 Nov; 5(11):e13838. PubMed ID: 21079803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial.
    Aponte JJ; Aide P; Renom M; Mandomando I; Bassat Q; Sacarlal J; Manaca MN; Lafuente S; Barbosa A; Leach A; Lievens M; Vekemans J; Sigauque B; Dubois MC; Demoitié MA; Sillman M; Savarese B; McNeil JG; Macete E; Ballou WR; Cohen J; Alonso PL
    Lancet; 2007 Nov; 370(9598):1543-51. PubMed ID: 17949807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant Liver Stage Antigen-1 (LSA-1) formulated with AS01 or AS02 is safe, elicits high titer antibody and induces IFN-gamma/IL-2 CD4+ T cells but does not protect against experimental Plasmodium falciparum infection.
    Cummings JF; Spring MD; Schwenk RJ; Ockenhouse CF; Kester KE; Polhemus ME; Walsh DS; Yoon IK; Prosperi C; Juompan LY; Lanar DE; Krzych U; Hall BT; Ware LA; Stewart VA; Williams J; Dowler M; Nielsen RK; Hillier CJ; Giersing BK; Dubovsky F; Malkin E; Tucker K; Dubois MC; Cohen JD; Ballou WR; Heppner DG
    Vaccine; 2010 Jul; 28(31):5135-44. PubMed ID: 19737527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants.
    Abdulla S; Oberholzer R; Juma O; Kubhoja S; Machera F; Membi C; Omari S; Urassa A; Mshinda H; Jumanne A; Salim N; Shomari M; Aebi T; Schellenberg DM; Carter T; Villafana T; Demoitié MA; Dubois MC; Leach A; Lievens M; Vekemans J; Cohen J; Ballou WR; Tanner M
    N Engl J Med; 2008 Dec; 359(24):2533-44. PubMed ID: 19064623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 2a trial of 0, 1, and 3 month and 0, 7, and 28 day immunization schedules of malaria vaccine RTS,S/AS02 in malaria-naïve adults at the Walter Reed Army Institute of Research.
    Kester KE; Cummings JF; Ockenhouse CF; Nielsen R; Hall BT; Gordon DM; Schwenk RJ; Krzych U; Holland CA; Richmond G; Dowler MG; Williams J; Wirtz RA; Tornieporth N; Vigneron L; Delchambre M; Demoitie MA; Ballou WR; Cohen J; Heppner DG;
    Vaccine; 2008 Apr; 26(18):2191-202. PubMed ID: 18387719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and immunogenicty of RTS,S/AS02A candidate malaria vaccine in Gambian children.
    Bojang KA; Olodude F; Pinder M; Ofori-Anyinam O; Vigneron L; Fitzpatrick S; Njie F; Kassanga A; Leach A; Milman J; Rabinovich R; McAdam KP; Kester KE; Heppner DG; Cohen JD; Tornieporth N; Milligan PJ
    Vaccine; 2005 Jul; 23(32):4148-57. PubMed ID: 15964483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the immune response to RTS,S/AS01 and RTS,S/AS02 adjuvanted vaccines: randomized, double-blind study in malaria-naïve adults.
    Leroux-Roels G; Leroux-Roels I; Clement F; Ofori-Anyinam O; Lievens M; Jongert E; Moris P; Ballou WR; Cohen J
    Hum Vaccin Immunother; 2014; 10(8):2211-9. PubMed ID: 25424924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial.
    Alonso PL; Sacarlal J; Aponte JJ; Leach A; Macete E; Aide P; Sigauque B; Milman J; Mandomando I; Bassat Q; Guinovart C; Espasa M; Corachan S; Lievens M; Navia MM; Dubois MC; Menendez C; Dubovsky F; Cohen J; Thompson R; Ballou WR
    Lancet; 2005 Dec; 366(9502):2012-8. PubMed ID: 16338450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults.
    Moorthy VS; Imoukhuede EB; Milligan P; Bojang K; Keating S; Kaye P; Pinder M; Gilbert SC; Walraven G; Greenwood BM; Hill AS
    PLoS Med; 2004 Nov; 1(2):e33. PubMed ID: 15526058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cellular immunity induced by the recombinant Plasmodium falciparum malaria vaccine, RTS,S/AS02, in semi-immune adults in The Gambia.
    Pinder M; Reece WH; Plebanski M; Akinwunmi P; Flanagan KL; Lee EA; Doherty T; Milligan P; Jaye A; Tornieporth N; Ballou R; McAdam KP; Cohen J; Hill AV
    Clin Exp Immunol; 2004 Feb; 135(2):286-93. PubMed ID: 14738458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The malaria vaccine--status quo 2013.
    Heppner DG
    Travel Med Infect Dis; 2013; 11(1):2-7. PubMed ID: 23454205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.